PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Partnership with CDMO Alcami for Exclusive Producg Formulation

May 25, 2021 09:12:07

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for the treatment diseases with unmet medical needs through accelerated regulatory pathways, has entered into an agreement with Alcami Corporation, a global pharmaceutical contract development and manufacturing organization (“CDMO”). The agreement marks Tryp’s next step in the proprietary manufacturing, formulation and delivery of products for its Psilocybin-for-Neuropsychiatric Disorder, PFN(TM) (“PFN”) program. The agreement is focused on developing oral formulations for Tryp’s proprietary psilocybin active pharmaceutical ingredient (“API”), which is being manufactured by Albany Molecular Research, Inc. The announcement noted Alcami’s broad capabilities, technical expertise and ability to collaborate with customers to consistently deliver high-quality results. Tryp is tentatively planning to manufacture an initial batch of cGMP psilocybin API by September 2021, after which Alcami and Tryp will develop the analytical methods and the final formulation of Tryp’s oral psilocybin product. “Our partnership with Alcami signals the further advancement of our proprietary manufacturing of synthetic psilocybin,” said Tryp president and chief science officer Jim Gilligan, PhD, in the release. “We have been impressed with Alcami’s expertise with developing both final formulations as well as the analytical methods that will ensure the consistently excellent quality of our products.”

To view the full press release, visit

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing clinical-stage compounds for the treatment diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders, or PFN(TM), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than 5 million people in the United States. The company is also preparing to initiate a phase 2a clinical study for eating disorders in partnership with Dr. Jennifer Miller at the University of Florida. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to Tare available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.